NCT02577341View on ClinicalTrials.gov

Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

122

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 30, 2020

Study Completion Date

October 31, 2020

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG

Nimotuzumab

Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.

DRUG

docetaxel and cisplatin

Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy

RADIATION

daily RT to the chest

Patients received daily RT to the chest

Trial Locations (1)

510000

Sun yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT02577341 - Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer | Biotech Hunter | Biotech Hunter